Comparative efficacy and safety profile of once-weekly Semaglutide versus once-daily Sitagliptin as an add-on to metformin in patients with type 2 diabetes: a systematic review and meta-analysis.
Tirath PatelFnu NageetaRohab SohailTooba Shaukat ButtShyamala GanesanFnu MadhuritaMuhammad AhmedMahrukh ZafarWirda ZafarMuhammad Uzair ZamanGiustino VarrassiMahima KhatriSatesh KumarPublished in: Annals of medicine (2023)
In conclusion, the administration of once-weekly Semaglutide exhibited a substantial reduction in HbA1c, average systolic blood pressure (SBP), mean diastolic blood pressure (DBP), body weight, waist circumference, body mass index (BMI), and a rise in pulse rate, as opposed to the once-daily administration of Sitagliptin.